ParkinsonCanadaV1, Main, Exploration, bibRecord, 001567

Transgenic conversion of omega-6 into omega-3 fatty acids in a mouse model of Parkinson's disease

Identifieur interne : 001567 ( Main/Exploration ); précédent : 001566; suivant : 001568

Transgenic conversion of omega-6 into omega-3 fatty acids in a mouse model of Parkinson's disease

Auteurs : Melanie Bousquet [Canada] ; Karl Gue [Canada] ; Vincent Emond [Canada] ; Pierre Julien [États-Unis] ; Jing X. Kang [États-Unis] ; Francesca Cicchetti [Canada] ; Frederic Calon [Canada]

Source :

Journal of Lipid Research [ 0022-2275 ] ; 2011.

RBID : PMC:3023546

English descriptors

KwdEn :
- Animals, Disease Models, Animal, Docosahexaenoic Acids (metabolism), Fatty Acids, Omega-3 (metabolism), Mice, Neuroprotective Agents (pharmacology), Parkinson Disease, Secondary (chemically induced), Parkinson Disease, Secondary (metabolism), Transgenes.
MESH :
- chemical , metabolism : Docosahexaenoic Acids, Fatty Acids, Omega-3.
- chemical , pharmacology : Neuroprotective Agents.
- chemically induced : Parkinson Disease, Secondary.
- metabolism : Parkinson Disease, Secondary.
- Animals, Disease Models, Animal, Mice, Transgenes.

Abstract

We have recently identified a neuroprotective role for omega-3 polyunsaturated fatty acids (n-3 PUFAs) in a toxin-induced mouse model of Parkinson's disease (PD). Combined with epidemiological data, these observations suggest that low n-3 PUFA intake is a modifiable environmental risk factor for PD. In order to strengthen these preclinical findings as prerequisite to clinical trials, we further investigated the neuroprotective role of n-3 PUFAs in Fat-1 mice, a transgenic model expressing an n-3 fatty acid desaturase converting n-6 PUFAs into n-3 PUFAs. Here, we report that the expression of the fat-1 transgene increased cortical n-3:n-6 PUFA ratio (+28%), but to a lesser extent than dietary supplementation (92%). Such a limited endogenous production of n-3 PUFAs in the Fat-1 mouse was insufficient to confer neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity as assessed by dopamine levels, tyrosine hydroxylase (TH)-positive neurons and fibers, as well as nigral Nurr1 and dopamine transporter (DAT) mRNA expression. Nevertheless, higher cortical docosahexaenoic acid (DHA) concentrations were positively correlated with markers of nigral dopaminergic neurons such as the number of TH-positive cells, in addition to Nurr1 and DAT mRNA levels. These associations are consistent with the protective role of DHA in a mouse model of PD. Taken together, these data suggest that dietary intake of a preformed DHA supplement is more effective in reaching the brain and achieving neuroprotection in an animal model of PD.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3023546

DOI: 10.1194/jlr.M011692
PubMed: 21115966
PubMed Central: 3023546

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Transgenic conversion of omega-6 into omega-3 fatty acids in a mouse model of Parkinson's disease</title>
<author><name sortKey="Bousquet, Melanie" sort="Bousquet, Melanie" uniqKey="Bousquet M" first="Melanie" last="Bousquet">Melanie Bousquet</name>
<affiliation wicri:level="1"><nlm:aff id="aff1">Centre de Recherche du CHUL (CHUQ), Axe Neurosciences, Québec, QC, Canada</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Centre de Recherche du CHUL (CHUQ), Axe Neurosciences, Québec, QC</wicri:regionArea>
<wicri:noRegion>QC</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:aff id="aff2">Faculté de Pharmacie, Université Laval, Québec, QC, Canada</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Faculté de Pharmacie, Université Laval, Québec, QC</wicri:regionArea>
<wicri:noRegion>QC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Gue, Karl" sort="Gue, Karl" uniqKey="Gue K" first="Karl" last="Gue">Karl Gue</name>
<affiliation wicri:level="1"><nlm:aff id="aff1">Centre de Recherche du CHUL (CHUQ), Axe Neurosciences, Québec, QC, Canada</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Centre de Recherche du CHUL (CHUQ), Axe Neurosciences, Québec, QC</wicri:regionArea>
<wicri:noRegion>QC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Emond, Vincent" sort="Emond, Vincent" uniqKey="Emond V" first="Vincent" last="Emond">Vincent Emond</name>
<affiliation wicri:level="1"><nlm:aff id="aff1">Centre de Recherche du CHUL (CHUQ), Axe Neurosciences, Québec, QC, Canada</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Centre de Recherche du CHUL (CHUQ), Axe Neurosciences, Québec, QC</wicri:regionArea>
<wicri:noRegion>QC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Julien, Pierre" sort="Julien, Pierre" uniqKey="Julien P" first="Pierre" last="Julien">Pierre Julien</name>
<affiliation wicri:level="2"><nlm:aff id="aff4">Centre de Recherche sur les Maladies Lipidiques, CHUL (CHUQ), Québec, QC, Canada, Massachusetts General Hospital and Medical School, Boston, MA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Centre de Recherche sur les Maladies Lipidiques, CHUL (CHUQ), Québec, QC, Canada, Massachusetts General Hospital and Medical School, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Kang, Jing X" sort="Kang, Jing X" uniqKey="Kang J" first="Jing X." last="Kang">Jing X. Kang</name>
<affiliation wicri:level="2"><nlm:aff id="aff5">Department of Medicine, Massachusetts General Hospital and Medical School, Boston, MA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Department of Medicine, Massachusetts General Hospital and Medical School, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Cicchetti, Francesca" sort="Cicchetti, Francesca" uniqKey="Cicchetti F" first="Francesca" last="Cicchetti">Francesca Cicchetti</name>
<affiliation wicri:level="1"><nlm:aff id="aff1">Centre de Recherche du CHUL (CHUQ), Axe Neurosciences, Québec, QC, Canada</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Centre de Recherche du CHUL (CHUQ), Axe Neurosciences, Québec, QC</wicri:regionArea>
<wicri:noRegion>QC</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:aff id="aff3">Département de Psychiatrie & Neurosciences, Faculté de Médecine, Université Laval, Québec, QC, Canada</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Département de Psychiatrie & Neurosciences, Faculté de Médecine, Université Laval, Québec, QC</wicri:regionArea>
<wicri:noRegion>QC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Calon, Frederic" sort="Calon, Frederic" uniqKey="Calon F" first="Frederic" last="Calon">Frederic Calon</name>
<affiliation wicri:level="1"><nlm:aff id="aff1">Centre de Recherche du CHUL (CHUQ), Axe Neurosciences, Québec, QC, Canada</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Centre de Recherche du CHUL (CHUQ), Axe Neurosciences, Québec, QC</wicri:regionArea>
<wicri:noRegion>QC</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:aff id="aff2">Faculté de Pharmacie, Université Laval, Québec, QC, Canada</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Faculté de Pharmacie, Université Laval, Québec, QC</wicri:regionArea>
<wicri:noRegion>QC</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">21115966</idno>
<idno type="pmc">3023546</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3023546</idno>
<idno type="RBID">PMC:3023546</idno>
<idno type="doi">10.1194/jlr.M011692</idno>
<date when="2011">2011</date>
<idno type="wicri:Area/Pmc/Corpus">000585</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000585</idno>
<idno type="wicri:Area/Pmc/Curation">000585</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000585</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000886</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000886</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="wicri:Area/PubMed/Corpus">000C50</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000C50</idno>
<idno type="wicri:Area/PubMed/Curation">000C50</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000C50</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000C50</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000C50</idno>
<idno type="wicri:Area/Ncbi/Merge">000D85</idno>
<idno type="wicri:Area/Ncbi/Curation">000D85</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000D85</idno>
<idno type="wicri:doubleKey">0022-2275:2011:Bousquet M:transgenic:conversion:of</idno>
<idno type="wicri:Area/Main/Merge">001631</idno>
<idno type="wicri:Area/Main/Curation">001567</idno>
<idno type="wicri:Area/Main/Exploration">001567</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Transgenic conversion of omega-6 into omega-3 fatty acids in a mouse model of Parkinson's disease</title>
<author><name sortKey="Bousquet, Melanie" sort="Bousquet, Melanie" uniqKey="Bousquet M" first="Melanie" last="Bousquet">Melanie Bousquet</name>
<affiliation wicri:level="1"><nlm:aff id="aff1">Centre de Recherche du CHUL (CHUQ), Axe Neurosciences, Québec, QC, Canada</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Centre de Recherche du CHUL (CHUQ), Axe Neurosciences, Québec, QC</wicri:regionArea>
<wicri:noRegion>QC</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:aff id="aff2">Faculté de Pharmacie, Université Laval, Québec, QC, Canada</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Faculté de Pharmacie, Université Laval, Québec, QC</wicri:regionArea>
<wicri:noRegion>QC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Gue, Karl" sort="Gue, Karl" uniqKey="Gue K" first="Karl" last="Gue">Karl Gue</name>
<affiliation wicri:level="1"><nlm:aff id="aff1">Centre de Recherche du CHUL (CHUQ), Axe Neurosciences, Québec, QC, Canada</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Centre de Recherche du CHUL (CHUQ), Axe Neurosciences, Québec, QC</wicri:regionArea>
<wicri:noRegion>QC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Emond, Vincent" sort="Emond, Vincent" uniqKey="Emond V" first="Vincent" last="Emond">Vincent Emond</name>
<affiliation wicri:level="1"><nlm:aff id="aff1">Centre de Recherche du CHUL (CHUQ), Axe Neurosciences, Québec, QC, Canada</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Centre de Recherche du CHUL (CHUQ), Axe Neurosciences, Québec, QC</wicri:regionArea>
<wicri:noRegion>QC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Julien, Pierre" sort="Julien, Pierre" uniqKey="Julien P" first="Pierre" last="Julien">Pierre Julien</name>
<affiliation wicri:level="2"><nlm:aff id="aff4">Centre de Recherche sur les Maladies Lipidiques, CHUL (CHUQ), Québec, QC, Canada, Massachusetts General Hospital and Medical School, Boston, MA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Centre de Recherche sur les Maladies Lipidiques, CHUL (CHUQ), Québec, QC, Canada, Massachusetts General Hospital and Medical School, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Kang, Jing X" sort="Kang, Jing X" uniqKey="Kang J" first="Jing X." last="Kang">Jing X. Kang</name>
<affiliation wicri:level="2"><nlm:aff id="aff5">Department of Medicine, Massachusetts General Hospital and Medical School, Boston, MA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Department of Medicine, Massachusetts General Hospital and Medical School, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Cicchetti, Francesca" sort="Cicchetti, Francesca" uniqKey="Cicchetti F" first="Francesca" last="Cicchetti">Francesca Cicchetti</name>
<affiliation wicri:level="1"><nlm:aff id="aff1">Centre de Recherche du CHUL (CHUQ), Axe Neurosciences, Québec, QC, Canada</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Centre de Recherche du CHUL (CHUQ), Axe Neurosciences, Québec, QC</wicri:regionArea>
<wicri:noRegion>QC</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:aff id="aff3">Département de Psychiatrie & Neurosciences, Faculté de Médecine, Université Laval, Québec, QC, Canada</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Département de Psychiatrie & Neurosciences, Faculté de Médecine, Université Laval, Québec, QC</wicri:regionArea>
<wicri:noRegion>QC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Calon, Frederic" sort="Calon, Frederic" uniqKey="Calon F" first="Frederic" last="Calon">Frederic Calon</name>
<affiliation wicri:level="1"><nlm:aff id="aff1">Centre de Recherche du CHUL (CHUQ), Axe Neurosciences, Québec, QC, Canada</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Centre de Recherche du CHUL (CHUQ), Axe Neurosciences, Québec, QC</wicri:regionArea>
<wicri:noRegion>QC</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:aff id="aff2">Faculté de Pharmacie, Université Laval, Québec, QC, Canada</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Faculté de Pharmacie, Université Laval, Québec, QC</wicri:regionArea>
<wicri:noRegion>QC</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Journal of Lipid Research</title>
<idno type="ISSN">0022-2275</idno>
<idno type="eISSN">1539-7262</idno>
<imprint><date when="2011">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Disease Models, Animal</term>
<term>Docosahexaenoic Acids (metabolism)</term>
<term>Fatty Acids, Omega-3 (metabolism)</term>
<term>Mice</term>
<term>Neuroprotective Agents (pharmacology)</term>
<term>Parkinson Disease, Secondary (chemically induced)</term>
<term>Parkinson Disease, Secondary (metabolism)</term>
<term>Transgenes</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Docosahexaenoic Acids</term>
<term>Fatty Acids, Omega-3</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Neuroprotective Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinson Disease, Secondary</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Parkinson Disease, Secondary</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Disease Models, Animal</term>
<term>Mice</term>
<term>Transgenes</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p>We have recently identified a neuroprotective role for omega-3 polyunsaturated fatty acids (n-3 PUFAs) in a toxin-induced mouse model of Parkinson's disease (PD). Combined with epidemiological data, these observations suggest that low n-3 PUFA intake is a modifiable environmental risk factor for PD. In order to strengthen these preclinical findings as prerequisite to clinical trials, we further investigated the neuroprotective role of n<italic>-</italic>
3 PUFAs in Fat-1 mice, a transgenic model expressing an n<italic>-</italic>
3 fatty acid desaturase converting n<italic>-</italic>
6 PUFAs into n<italic>-</italic>
3 PUFAs. Here, we report that the expression of the <italic>fat-1</italic>
 transgene increased cortical n<italic>-</italic>
3:n<italic>-</italic>
6 PUFA ratio (+28%), but to a lesser extent than dietary supplementation (92%). Such a limited endogenous production of n<italic>-</italic>
3 PUFAs in the Fat-1 mouse was insufficient to confer neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity as assessed by dopamine levels, tyrosine hydroxylase (TH)-positive neurons and fibers, as well as nigral Nurr1 and dopamine transporter (DAT) mRNA expression. Nevertheless, higher cortical docosahexaenoic acid (DHA) concentrations were positively correlated with markers of nigral dopaminergic neurons such as the number of TH-positive cells, in addition to Nurr1 and DAT mRNA levels. These associations are consistent with the protective role of DHA in a mouse model of PD. Taken together, these data suggest that dietary intake of a preformed DHA supplement is more effective in reaching the brain and achieving neuroprotection in an animal model of PD.</p>
</div>
</front>
</TEI>
<affiliations><list><country><li>Canada</li>
<li>États-Unis</li>
</country>
<region><li>Massachusetts</li>
</region>
</list>
<tree><country name="Canada"><noRegion><name sortKey="Bousquet, Melanie" sort="Bousquet, Melanie" uniqKey="Bousquet M" first="Melanie" last="Bousquet">Melanie Bousquet</name>
</noRegion>
<name sortKey="Bousquet, Melanie" sort="Bousquet, Melanie" uniqKey="Bousquet M" first="Melanie" last="Bousquet">Melanie Bousquet</name>
<name sortKey="Calon, Frederic" sort="Calon, Frederic" uniqKey="Calon F" first="Frederic" last="Calon">Frederic Calon</name>
<name sortKey="Calon, Frederic" sort="Calon, Frederic" uniqKey="Calon F" first="Frederic" last="Calon">Frederic Calon</name>
<name sortKey="Cicchetti, Francesca" sort="Cicchetti, Francesca" uniqKey="Cicchetti F" first="Francesca" last="Cicchetti">Francesca Cicchetti</name>
<name sortKey="Cicchetti, Francesca" sort="Cicchetti, Francesca" uniqKey="Cicchetti F" first="Francesca" last="Cicchetti">Francesca Cicchetti</name>
<name sortKey="Emond, Vincent" sort="Emond, Vincent" uniqKey="Emond V" first="Vincent" last="Emond">Vincent Emond</name>
<name sortKey="Gue, Karl" sort="Gue, Karl" uniqKey="Gue K" first="Karl" last="Gue">Karl Gue</name>
</country>
<country name="États-Unis"><region name="Massachusetts"><name sortKey="Julien, Pierre" sort="Julien, Pierre" uniqKey="Julien P" first="Pierre" last="Julien">Pierre Julien</name>
</region>
<name sortKey="Kang, Jing X" sort="Kang, Jing X" uniqKey="Kang J" first="Jing X." last="Kang">Jing X. Kang</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001567 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001567 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     PMC:3023546
   |texte=   Transgenic conversion of omega-6 into omega-3 fatty acids in a mouse model of Parkinson's disease
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:21115966" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a ParkinsonCanadaV1

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

La maladie de Parkinson au Canada (serveur d'exploration)

Transgenic conversion of omega-6 into omega-3 fatty acids in a mouse model of Parkinson's disease

Transgenic conversion of omega-6 into omega-3 fatty acids in a mouse model of Parkinson's disease

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.